Antwerp, Belgium, April 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today reported financial results for the full year period ended December 31, 2025, and confirmed its outlook for 2026. — Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of …
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“’Agomab’”), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company’s investigational inhaled lung-restricted small molecule inhibitor
ANTWERP, Belgium, February 9, 2026 AgomAb Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the closing of its previously announced initial public offering of 12,500,000 American Depositary Shares
ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the pricing of its initial public offering of 12,500,000 American Depositary Shares
ANTWERP, Belgium, February 2, 2026. Agomab Therapeutics NV (“Agomab”), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the launch of its initial public offering of 12,500,000 American Depositary Shares (“ADSs”), each ADS representing
Antwerp, Belgium, January 8, 2026 Agomab Therapeutics NV (‘Agomab’), a clinical-stage biopharmaceutical company focused on fibrosis, today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants. AGMB-447 is an inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Recent Comments